The Medical Biotechnology Laboratory of the Austral University of Chile is conducting research with alpaca nanobodies for effective diagnosis, treatment and prophylactic measures against COVID-19. The developed method allows the rapid isolation of alpaca nanobodies with subnanomolar affinity against spike RBD of SARS-CoV-2 by combining bacterial imaging and a simple one-step density gradient selection. For the assays, the Austral University of Chile used recombinant SARS-CoV-2 (2019-nCoV) spike S1 protein (RBD) from trenzyme. The complete paper can be found here: